Contributions
Abstract: P1321
Type: Poster
Abstract Category: RIMS - Neurobiology & Rehabilitation
Introduction: Prolonged-release fampridine (PRF) has been shown in multiple sclerosis (MS) patients to improve walking capabilities by more than 20% in approximately 34% of subjects. Active motor training in MS patients is both feasible and beneficial. Studies have shown it to improve walking ability, fatigue, depressive symptoms and cognition. The objective of our study is to test the hypothesis that active motor training when combined with PRF in patients with MS will produce a larger and more sustained measurable clinical benefit than with active motor training alone.
Methods: Phase 4, single center, double-blind placebo-controlled 14 week study. Patients were randomized to receive PRF 10 mg or placebo BID. All patients underwent active motor training as per the NeuroGym method consisting of 3, I hour session, per week for a period of 6 weeks (total of 18 sessions).Patients were evaluated at times -4, 0, 6, and 14 weeks using the timed 8 meter walk (T8MW), the six minute walk (6MW) and the Five-Times-Sit-to-Stand (FTSST).A responder was defined as a patient who improved more than 20% from baseline in a specific task and time point. Mean percent improvement was measured for the whole group (PRF or placebo) for a task and time point.
Results: 37 patients completed the study. There were no statistical difference between the two groups at baseline. A measurable benefit was noted from the training in both groups which was sustained at week 14. The greatest improvement in both groups was noted in the sit to stand measure with an OR of 2.7 (p=0.13) of being a responder in the PRF treated group. The incidence of responders was higher in the PRF treated group and ranged from 22 to 66% ( p =0.1 or more) The PRF treated group showed a higher mean percent improvement in all three measurements at both time points but this did not reach statistical significance. (p values ranging from 0.07 to 0.4)
Conclusions: MS patients can obtain a sustained benefit from strength training. PRF appears to increase the degree of improvement at both the individual and the group level. The latter will need to be confirmed in a larger trial.
Disclosure: the study was funded by an unrestricted grant from Biogen
Dr F jacques has received honoraria from Biogen
Dr a Nativ if the proprietor of Neuro-Gym
DR A J Schembri has nothing to dosclose
C Paquette has nothing to disclose
P Kalinowski has nothing to disclose
Abstract: P1321
Type: Poster
Abstract Category: RIMS - Neurobiology & Rehabilitation
Introduction: Prolonged-release fampridine (PRF) has been shown in multiple sclerosis (MS) patients to improve walking capabilities by more than 20% in approximately 34% of subjects. Active motor training in MS patients is both feasible and beneficial. Studies have shown it to improve walking ability, fatigue, depressive symptoms and cognition. The objective of our study is to test the hypothesis that active motor training when combined with PRF in patients with MS will produce a larger and more sustained measurable clinical benefit than with active motor training alone.
Methods: Phase 4, single center, double-blind placebo-controlled 14 week study. Patients were randomized to receive PRF 10 mg or placebo BID. All patients underwent active motor training as per the NeuroGym method consisting of 3, I hour session, per week for a period of 6 weeks (total of 18 sessions).Patients were evaluated at times -4, 0, 6, and 14 weeks using the timed 8 meter walk (T8MW), the six minute walk (6MW) and the Five-Times-Sit-to-Stand (FTSST).A responder was defined as a patient who improved more than 20% from baseline in a specific task and time point. Mean percent improvement was measured for the whole group (PRF or placebo) for a task and time point.
Results: 37 patients completed the study. There were no statistical difference between the two groups at baseline. A measurable benefit was noted from the training in both groups which was sustained at week 14. The greatest improvement in both groups was noted in the sit to stand measure with an OR of 2.7 (p=0.13) of being a responder in the PRF treated group. The incidence of responders was higher in the PRF treated group and ranged from 22 to 66% ( p =0.1 or more) The PRF treated group showed a higher mean percent improvement in all three measurements at both time points but this did not reach statistical significance. (p values ranging from 0.07 to 0.4)
Conclusions: MS patients can obtain a sustained benefit from strength training. PRF appears to increase the degree of improvement at both the individual and the group level. The latter will need to be confirmed in a larger trial.
Disclosure: the study was funded by an unrestricted grant from Biogen
Dr F jacques has received honoraria from Biogen
Dr a Nativ if the proprietor of Neuro-Gym
DR A J Schembri has nothing to dosclose
C Paquette has nothing to disclose
P Kalinowski has nothing to disclose